The National Center Biobank Network (NCBN) in Japan has surpassed 250,000 registered participants and holds over 800,000 biospecimens across more than 200 disease types as of March 2026, establishing itself as Japan’s leading disease-oriented biobank in both quality and quantity.

The NCBN Catalogue Database enables centralized searching across all six biobanks, with enhancements for ICD-10 classification and exclusion searches to improve resource discovery.

Researchers can access resources via two models: collaborative research with NCBN institutions or provision (a fee-based model granting users ownership of resulting IP); in 2025 the NCC began offering provision, expanding this option across more centers, with overseas access possible through joint research.

Samples primarily include blood and DNA, but may also comprise cerebrospinal fluid and frozen tissue, all accompanied by physician-curated clinical records and preanalytical quality data; some samples include whole-genome sequencing data, enabling translational research and genomic medicine in Japan.

Key discoveries illustrate the network’s strengths: at NCC, a mutational signature appears in over 70% of Japanese clear cell renal cell carcinoma cases versus under 2% elsewhere; NCVC’s time-series samples linked RNF213 mutations to altered cardiac-pulmonary blood flow and higher risk of refractory pulmonary hypertension; NCNP’s CSF studies supported BMP4’s role in cognitive decline and neurogenesis failure in Alzheimer’s disease; JIHS contributed data to the COVID-19 Host Genetics Initiative identifying a deleterious TLR7 variant increasing severe COVID-19 risk; NCCHD found a patient-specific ZNF254 promoter methylation change related to gonadotropin deficiency; NCGG’s dementia-focused GWAS highlighted a locus involving DAPK2 and created an integrated dementia data platform combining clinical, imaging, and omics data.

Beyond disease samples, NCBN completed whole-genome sequencing of 9,850 controls (NCBN Control) to support Japan’s national genomics initiatives, including focus on the Ryukyuan population; data are accessible through the NBDC Human Database and MGeND, with data used in multiple collaborative studies and papers.

Overall, the NCBN offers uniquely deeply phenotyped patient biospecimens and longitudinal clinical data, distinguishing it from population-based biobanks and positioning it as a critical platform for precision medicine and translational research in Japan.

NCBN is a federated network of six biobanks operated by national centers for advanced and specialized medicine, with centers in Tokyo, Osaka, and Aichi, each focusing on specific disease areas such as cancer, cardiovascular disease, psychiatric and neurological disorders, pediatric/obstetric conditions, and age-related diseases; the Japan Institute for Health Security (JIHS) now oversees the infectious disease biobank following a 2025 structural reform.

Quality assurance is a global priority, with ISO 20387 standards guiding biobank accreditation; four Japanese biobanks, including NCGG and NCNP, received accreditation in March 2024, and expansion to all NCBN biobanks is under consideration, contributing to Biobank Network Japan alongside Biobank Japan and the Tohoku Medical Megabank.